4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models
Journal for ImmunoTherapy of Cancer · 2025-02 · 13 (2) · e009852
DOI: 10.1136/jitc-2024-009852 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 11.02.2025. Verfasst von Eneko Garate-Soraluze und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain. Hauptthemen laut MEDLINE: Serine Endopeptidases, Gelatinases, Membrane Proteins, Tumor Necrosis Factor Receptor Superfamily, Member 9. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CRIS Cancer Foundation, imCORE Network on behalf of F. Hoffmann-La Roche, Fundación Científica Asociación Española Contra el Cáncer.
Abstract (Originalsprache)
Background
Ionizing radiation (IR) is a double-edged sword for immunotherapy as it may have both immunosuppressive and immunostimulatory effects. The biological effects of IR on the tumor microenvironment (TME) are a key factor for this balance. Fibroblast activation protein (FAP) is expressed on the surface of cancer-associated fibroblasts (CAF) in many cancer types and its abundance is associated with the poor immune response to immune-checkpoint-blockade in patients. We hypothesized that IR increases FAP expression in CAFs, therefore the combination of IR with targeted immunomodulators such as an agonistic anti-FAP-4-1BBL fusion protein could enhance the immune-mediated antitumoral effects of these treatments.
Methods
The murine transplantable TS/A tumor-cell-line co-engrafted with CAFs was used to investigate increases in FAP expression in tumors following irradiation using immunohistochemistry, real-time polymerase chain reaction (RT-PCR) and multiplex tissue immunofluorescence. One lesion of bilateral tumor-bearing mice was only locally irradiated or combined with weekly injections of the bispecific muFAP-4-1BBL fusion protein (a mouse surrogate for RG7826). Tumor sizes were followed over time and TME was assessed by flow cytometry. Selective monoclonal antibody (mAb)-mediated depletions of immune cell populations, neutralizing interferon alpha/beta receptor 1 (IFNAR-I) IFNAR and interferon (IFN)-γ mAbs and gene-modified mice (4-1BB −/− ) were used to delineate the immune cell subsets and mechanisms required for efficacy. 67 Ga labeled muFAP-4-1BBL tracked by SPECT-CT was used to study biodistribution. In human colorectal carcinoma samples, the inducibility of FAP expression following radiotherapy was explored by multiplex immunofluorescence.
Results
Irradiation of TS/A+CAF tumors in mice showed an increase in FAP levels after local irradiation. A suboptimal radiotherapy regimen in combination with muFAP-4-1BBL attained primary tumor control and measurable abscopal effects. Immune TME landscape analyses showed post-treatment increased infiltration of activated immune cells associated with the combined radioimmunotherapy treatment. Efficacy depended on CD8 + T cells, type I IFN, IFN-γ and ability to express 4-1BB. Biodistribution studies of muFAP-4-1BBL indicated enriched tumor targeting to irradiated tumors. Human colorectal cancer samples pre and post irradiation showed enhanced FAP expression after radiotherapy.
Conclusion
Increased FAP expression in the TME as a result of radiotherapy can be exploited to target agonist 4-1BB immunotherapy to malignant tumor lesions using an FAP-4-1BBL antibody fusion protein.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
- Department of Pathology, Cancer Center Clinica Universidad de Navarra, Pamplona, Spain.
- Department of Immunology, Hospital Gregorio Marañon, Madrid, Madrid, Spain.
- Roche Innovation Centre Zurich, Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland.
- Institute of Immunology and Transplantation, University College London, London, UK.
- Department of Nuclear Medicine, Clinica Universidad de Navarra, Pamplona, Spain.
Förderung
- CRIS Cancer Foundation
- imCORE Network on behalf of F. Hoffmann-La Roche
- Fundación Científica Asociación Española Contra el Cáncer
Zitieren
APA
Garate-Soraluze, E., Serrano-Mendioroz, I., Fernández-Rubio, L., De Andrea, C. E., Barrio-Alonso, C., Herrero, C. D. P., Teijeira, A., Luri-Rey, C., Claus, C., Tanos, T., Klein, C., Umana, P., Rullan, A., Simón, J. A., Collantes, M., Sánchez-Mateos, P., Melero, I., & Rodriguez-Ruiz, M. E. (2025). 4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models. Journal for ImmunoTherapy of Cancer, 13(2), e009852. https://doi.org/10.1136/jitc-2024-009852
Vancouver
Garate-Soraluze E, Serrano-Mendioroz I, Fernández-Rubio L, De Andrea CE, Barrio-Alonso C, Herrero CDP, et al. 4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models. Journal for ImmunoTherapy of Cancer. 2025;13(2):e009852. doi:10.1136/jitc-2024-009852
BibTeX
@article{GarateSoraluze2025,
author = {Garate-Soraluze, Eneko and Serrano-Mendioroz, Irantzu and Fernández-Rubio, Leticia and De Andrea, Carlos E and Barrio-Alonso, Celia and Herrero, Claudia Del Pilar and Teijeira, Alvaro and Luri-Rey, Carlos and Claus, Christina and Tanos, Tamara and Klein, Christian and Umana, Pablo and Rullan, Antonio and Simón, Jon Ander and Collantes, María and Sánchez-Mateos, Paloma and Melero, Ignacio and Rodriguez-Ruiz, Maria E},
title = {4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {2},
pages = {e009852},
doi = {10.1136/jitc-2024-009852}
}
EUVIMED